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The belief that infectious agents are a cause
of chronic inflammatory diseases of unknown
etiology and of cancer is not new. Approximately
100 years ago, doctors noted a connection
between cervical cancer and sexual promiscuity
that transcended mere coincidence (1). By 1911, a
connection between viruses and cancers in
animals had become well established (2). As early
as the 1930s, mycoplasmas were proposed as a
cause of rheumatoid arthritis in humans, and
shortly thereafter, they were proven to be the
most common cause of naturally occurring
chronic arthritis in animals (3). Proof of causality
of cancer and arthritis in humans was more
difficult. When searches for infectious agents in
cancer and arthritis found none, research began
to focus on mechanisms of inflammation,
tumorogenesis, and drug discovery. More re-
cently, however, scientists have renewed searches
for infectious agents.
Advances in molecular biology and medical
devices have revolutionized our ability to detect
very low numbers of infectious agents in
specimens collected directly from the affected
site. HIV has demonstrated the ability of
infectious agents to produce slowly progressive,
chronic disease with a wide spectrum of clinical
manifestations and disease outcomes. Increased
understanding of the body’s defense mechanisms
and the demonstration that final outcome of
infection is as much determined by the genetic
background of the host as by the genetic makeup
of the infecting agent suggest that a number of
chronic diseases of unknown etiology may be
caused by an infectious agent.
Recent data suggest a role for one or more
infectious agents in the following chronic diseases:
chronic lung diseases (including asthma), cardio-
vascular disease, and cancer. Many of the agents
implicated are commonly transmissible and are
either treatable with existing antibiotics or are
potentially treatable with antiviral drugs. Thus,
proof of causality in any one of these diseases
would have enormous implications for public
health, treatment, and prevention. Few areas of
research hold greater promise of contributing to
our understanding of infectious diseases and the
eventual relief of human suffering.
The intent of this paper is not to provide a
comprehensive review of chronic inflammatory
diseases of unknown etiology and the agents
implicated but rather to utilize several models to
discuss available data and to illustrate the
difficulty in proving causality in chronic
inflammatory diseases. The discussion is based
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upon the following assumptions. Most chronic
inflammatory diseases are likely multifactorial.
Heredity, environment, and nutrition are critical
determinants of disease expression with heredity
being the most important.
Theoretically, chronic inflammatory diseases
currently of unknown etiology could result from
three different types of pathogens: 1) those that
are fastidious and previously recognized but
because of their fastidiousness or lack of
appreciation of their disease-producing potential
are not included in the differential diagnosis, and
2) infectious agents previously not recognized
that therefore go undetected. Infection with
either group can result in misdiagnosis and lack
of treatment. Depending upon the biology of the
organism and intrinsic and extrinsic factors of
the host the organism can persist, resulting in
chronic inflammation. The third group of
pathogens would be those that elicit an
autoimmune response resulting in persistent
inflammation without the persistence of the
inciting agent. Examples of the first two groups of
pathogens will be discussed here using mycoplas-
mas to typify the first group and Chlamydia
pneumoniae the second. Finally, recent advances
in our understanding of the role of infectious
agents in cancer will also be summarized.
Chronic Lung Diseases
Murine Chronic Respiratory Disease as a
Model System
The difficulty in establishing the infectious
etiology of a chronic obstructive lung disease is
well illustrated by Mycoplasma pulmonis and
murine chronic respiratory disease. Proof that M.
pulmonis can cause this disease took nearly 50
years and required inoculation of germ-free
animals (4). Chronic bronchopneumonia in rats
was first described in 1915 when this species
came into general use for experimental purposes
(5). In approximately 1940, a Mycoplasma, later
identified as M. pulmonis, was recognized as a
possible cause (6), but the ubiquity of the
organism and its frequent isolation from healthy
as well as diseased rats and mice (even from
trachea and lungs) soon gave it the reputation of
being a commensal with little pathogenic
potential. The failure of pure cultures of this
organism to consistently produce disease of the
lower respiratory tract also precluded its
acceptance as the etiologic agent. Only in the
early 1970s was M. pulmonis alone shown to
consistently reproduce all of the characteristic
clinical and pathologic features of the natural
respiratory disease when inoculated into animals
maintained under germ-free conditions (7).
Subsequent studies provided explanations for
previous difficulties in reproducing the disease.
The respiratory disease caused by M.
pulmonis is slow to begin and long-lasting.
Consequently, the disease has various stages of
pathologic lesions and a lack of uniform lesions,
even among animals in the same cages (due
partly to variables that can affect development of
the disease in the lower respiratory tract, such as
intracage ammonia produced by bacterial action
on soiled bedding, synergy with murine respira-
tory viruses and other bacterial pathogens, and
nutritional factors) (7). However, comparison of
animals matched for age, sex, and microbial and
environmental factors indicates that heredity is
the most critical determinant of susceptibility,
lesion character, and disease severity. Suscepti-
bility among animal species and among strains of
the same species differ dramatically (8-11).
Intranasal inoculation of M. pulmonis
produces markedly different lesions in F344 rats
and in CD-1 mice, even when the dose is
comparable on the basis of lung and body weight.
In rats the lesions progress slowly from the upper
respiratory tract distally, with alveolar involve-
ment occurring days to months following
inoculation, whereas in mice, alveolar lesions
develop within hours after infection and are
responsible for acute alveolar disease and death
within 3 to 5 days. Depending on their genetic
background, mice that survive the acute disease
develop chronic lung disease characterized by
bronchiectasis that persists for up to 18 to 24
months or the lifetime of the animal.
Studies of naturally occurring and experi-
mentally induced disease indicate that M.
pulmonis also causes a slowly progressing upper
genital tract disease in LEW and F344 rats (18).
Pups can become infected in utero, at the time of
birth due to cervical and vaginal infection of the
dams, or via aerosol from dams shortly after
birth. Even though the organisms can be shown
to colonize the ciliated epithelium of the upper
and lower respiratory tracts of pups, microscopic
lesions are not detectable for 2 to 6 months
depending on the strain of rat. Development of
obstructive lung disease can require as long as 12
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Differences in severity and progression of the
lung lesions due to M. pulmonis in LEW and F344
rats are related to differences in the degree of
nonspecific lymphocyte activation in the two
strains or an imbalance in regulation of
lymphocyte proliferation in LEW rats (12). M.
pulmonis possesses a potent B cell mitogen, and,
in addition, the organism is chemotactic for B
cells (13). Interestingly, LEW rats are also more
susceptible to other chronic inflammatory
diseases, including streptococcal cell-wall in-
duced arthritis, adjuvant-induced arthritis, and
allergic encephalomyelitis (12).
Ureaplasma urealyticum as a Cause of
Pneumonia in Newborns and Its Association
with Chronic Lung Disease (CLD) in Premature
Infants
Respiratory dysfunction represents the most
common life-threatening problem in premature
infants and one of the largest costs of neonatal
intensive care (14). Infants weighing less than
1,000 g at birth are more likely than those with
greater birth weights to die within the first few
days of birth of respiratory-related problems;
those who survive are at an increased risk of CLD
(15). Approximately 20% of stillborn babies and
infants dying within 72 hours of delivery have
histologic evidence of pneumonia (16). Yet the
true incidence of lower respiratory infection
acquired either in utero or at the time of delivery
and its contribution to death or development of
CLD are unknown. The cause of lower
respiratory disease in newborn babies is a
diagnostic dilemma because pneumonia in early
neonatal life is usually clinically and radiologi-
cally indistinguishable from surfactant-defi-
ciency syndrome (17). Furthermore, meaningful
cultures from the lung are not easily obtained,
whereas cultures of the throat, nasopharynx, and
blood are unrevealing or misleading.
Pneumonia
The mycoplasma U. urealyticum, a common
commensal of the lower female genital tract, has
recently been shown to cause respiratory disease
in newborn infants. Retrospective (18) and
prospective (19-21) studies indicate an associa-
tion of U. urealyticum with congenital pneumo-
nia. Case reports also provide evidence that U.
urealyticum is a cause of pneumonia in newborn
infants (22-23). The organism has been isolated
from affected lungs in the absence of chlamydiae,
viruses, fungi, and bacteria and in the presence of
chorioamnionitis and funisitis (40) and has been
demonstrated within fetal membranes by
immunofluorescence (24) and in lung lesions of
newborns by electron and immunofluorescent
microscopy (20). The specific immunoglobulin (Ig)
M response in several cases of pneumonia in
newborns further documents in utero infection (20).
We have found that U. urealyticum is the
single most common microorganism isolated
from endotracheal aspirates of infants who weigh
£2,500 g and who require supplemental oxygen
within the first 24 hours after birth (19). Infants
weighing £1,000 g and from whom U. urealyticum
is isolated from the endotracheal aspirate are
twice as likely to die as infants of similar birth
weight but who are uninfected or infected infants
³1,000 g. These findings support the hypothesis
that only a select group of infants, i.e., those with
very low birth weights, is subject to disease due to
U. urealyticum. This fact may account for the
seeming disparities in conclusions regarding the
role of U. urealyticum in neonatal respiratory
disease reached in earlier prospective studies
that failed to distinguish this subpopulation at
high risk from the whole (25,26).
That endotracheal isolations of U. urealyticum
represent true infection of the lower respiratory
tract is supported by initial isolation of
ureaplasmas in numbers exceeding 1,000 CFUs
(and sometimes exceeding 10,000 CFUs) and
repeated isolations of the organism from tracheal
aspirates for weeks and even months in some
infants that continue to require mechanical
ventilation. That the tracheal isolates are not
merely a reflection of contamination from the
nasopharynx is supported by the discrepancy in
isolation rates between the two sites and recovery
of U. urealyticum in pure culture from
endotracheal aspirates in more than 85% of the
infants (19). Concomitant recovery of the
organism from blood of up to 26% of those with
positive endotracheal aspirates and from cere-
brospinal fluid (CSF) of some infants indicate
that in some infants the organism is invasive (19).
Fourteen percent of U. urealyticum endotracheal
isolates were from infants born by cesarean
section with intact membranes, indicating that in
utero transmission occurs rather commonly, at
least in premature infants.
In a study of 98 infants, respiratory distress
syndrome, the need for assisted ventilation,
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significantly more common among those infants
<34 weeks gestation from whom U. urealyticum
was recovered from endotracheal aspirates at the
time of delivery than among uninfected infants
(27). U. urealyticum was isolated from 34% of
blood cultures and also from four of six CSF
samples and in 6 of 11 postmortem brain and lung
biopsy pecimens. Eighty-two percent of the
ureaplasma isolates were present in pure culture,
and 48% of infants born by cesarean section with
intact membranes had ureaplasmas isolated
from one or more sites.
U. urealyticum can induce ciliostasis and
mucosal lesions in human fetal tracheal organ
cultures (20). Furthermore, we have shown that
ureaplasmas isolated from the lungs of human
infants with congenital and neonatal pneumonia
produce a histologically similar pneumonia in
newborn mice (28). Even in this mouse model, age
is a critical determinant of disease. Newborn
mice are susceptible to colonization of the
respiratory tract and development of pneumonia;
14-day-old mice are resistant.
We have shown that endotracheal inocula-
tion of premature baboons (well-established
models of premature human infants) with U.
urealyticum isolated from human infants results
in the development of pathologically recognizable
pulmonary lesions, including acute bronchiolitis
with epithelial ulceration and polymorpho-
nuclear infiltration, which is distinguishable
from hyaline membrane disease (29). U. urealyticum
can be isolated from blood, endotracheal aspirates,
and pleural fluid and lung tissue from some of
these animals 6 days after infection.
The available evidence provides a strong
argument that U. urealyticum is a common cause
of pneumonia in newborn infants, particularly
those born before 34 weeks of gestation. The
organism can be isolated from endotracheal
aspirates in up to 34% of infants weighing <2,500 g;
radiographic evidence of pneumonia is twice as
common in these infants as in U. urealyticum
negative infants (30% vs. 16%, p = .03) (30). Many
of these infections develop as a result of in utero
exposure. Cases of ureaplasmal pneumonia occur
much less frequently in term infants. These
findings in infants are consistent with the fact
that U. urealyticum infection of the chorioamnion
is also much more common before 34 weeks of
gestation. Lack of transplacental passage of
immunoglobulin prior to 32 weeks gestation (31)
may partially explain these findings. Experience
from mycoplasmal respiratory diseases of
animals indicates that preexisting antibody is
protective, whereas antibody in the presence of
an established infection is rarely effective in
elimination of the organism (32).
CLD in Premature Infants
Some, but not all, studies (33-36) show an
association between isolation of U. urealyticum
from the respiratory tract of newborn infants and
the development of CLD (33). Differing results
may be obtained because some studies do not
limit culture isolation to the affected site (the
lower respiratory tract), do not limit their patient
population to those at greatest risk (birth weight
<1,000 g); or do not limit culture isolation to
within 12 hours of delivery, i.e., most likely
infected in utero. Several facts suggest that
infants who acquire U. urealyticum in utero may
be at greatest risk for development of CLD. Dyke
et al. (34) found U. urealyticum in the gastric
aspirates of infants £1,000 g was associated with
a significantly increased risk of CLD in those
infants delivered by cesarean section but not in
those delivered vaginally. This could result from
a longer exposure to U.urealyticum as a result of
in utero exposure, or it may be a reflection of
differences in the virulence of those organisms
found only in the cervix versus those that have
invasive potential and that can cause an
ascending infection from the vagina into the
uterus. Along these lines it is of interest that a
recent study of 49 preterm infants which included
only three infants from whom U. urealyticum was
recovered within 24 hours of birth found no
association with development of CLD (35). The
remaining 11 infants were not culturally positive
until 48 to 72 hours after birth suggesting that
only the three study infants were infected in
utero. In another recent study reported by
Valencia et al. (36) CLD was found in 26% of U.
urealyticum infected infants compared to only
4.7% of the noncolonized group. However, these
results were not statistically significant possibly
because of the small number of patients studied
but also possibly because 22% of the patients
included did not have cultures performed until
between 2 days and 3 months postnatal life.
Isolation of U. urealyticum from endotra-
cheal aspirates is not only a risk factor for
development of pneumonia but also of precocious
dysplastic changes (30). Walsh et al. (38) isolated
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tissue collected by open lung biopsy in four of
eight infants cultured who had CLD. We (19)
continued to recover ureaplasmas from endotra-
cheal aspirates of infants with CLD for months
following initial recovery of the organism from
endotracheal aspirates within 12 hours of birth.
Available evidence creates a cohesive argu-
ment that U. urealyticum infection of the lower
respiratory tract is a likely risk factor for, and not
only associated with, CLD. Because U. urealyticum
has only recently been suggested as a cause of
pneumonia in newborns, it is not routinely sought
by most hospital laboratories. Furthermore, the
organism is not susceptible to antibiotics used
prophylactically in very low birth-weight infants
with evidence of respiratory distress. Conse-
quently, the infection, i.e., pneumonia, goes
undetected and untreated. Due to the difficulties
in diagnosis, most hospital laboratories do not
culture for this organism.
The pathophysiology of CLD in premature
infants suggests that U. urealyticum produces
undetected and untreated pneumonia and
results in an increased requirement for oxygen
and subsequent development of CLD as a result
of oxygen toxicity (33,37) or a synergistic effect
between the ureaplasmas and hyperoxia. It has
been proposed that hyperoxia-induced lung
injury contributes to development of CLD by
stimulating the proinflammatory cytokine
interleukin (IL)-6 (38). U. urealyticum may also
contribute to the development of CLD by
stimulation of proinflammatory cytokines. In-
fants from whom ureaplasmas are isolated from
endotracheal aspirates within the first 24 hours
of life are more likely to have neutrophils in their
tracheal aspirates on day 2 than are those not
colonized (39). Aspirates from colonized infants
are also more likely to have class II cytology than
those from uncolonized patients at day 2 of life.
This may explain why ureaplasma-infected
infants respond to dexamethasone therapy (39).
These in vivo findings are consistent with the
recent demonstration of U. urealyticum induc-
tion of IL-6 and IL-8 in human neonatal
pulmonary fibroblasts even in the absence of
hyperoxia (38). Interestingly, together
ureaplasmas and hyperoxia resulted in greater
stimulation of IL-6 and IL-8 than either alone.
This is consistent with the synergism previously
demonstrated in vivo between ureaplasmal
infection and hyperoxia (37).
Studies in mice also suggest that increased
oxygen requirements of very low birth-weight
infants might predispose them to lower respira-
tory tract infection or, alternatively, that U.
urealyticum infection potentiates oxygen-induced
injury (28,37). Exposure to oxidants is known to
enhance respiratory disease and death due to M.
pulmonis respiratory disease in mice (41).
That U. urealyticum is a cause of pneumonia
in newborns can no longer be questioned. Data
provide strong evidence that U. urealyticum can
be a primary cause or a contributing cofactor in
development of CLD in humans, but the data are
not definitive. Cohort studies allow follow-up of
exposed persons and thus reduce bias, but the
designs of these studies cannot rule out the
possibility that a third factor associated with
U. urealyticum is actually the true cause of
CLD. However, a randomized trial of exposure to
infection in humans is not ethical or practical.
Although a randomized trial of antibiotic
treatment could provide critical information
related to patient management, it would still not
bring us closer to proving causality. Even if
treatment is found to be efficacious, conclusions
about causation will be limited by the fact that
the third factor might also be susceptible to the
antibiotic chosen. If it is not found to be efficacious,
it may be because ureaplasma infection in utero or
soon after birth results in irreversible lung damage.
Nevertheless, a treatment trial is urgently needed
to determine whether appropriate therapy can
reduce the incidence of illness and death
associated with CLD. First, studies are needed to
determine dose and duration of antibiotic
therapy and whether currently available antibi-
otics will even eliminate the organism.
Mycoplasma pneumoniae and C. pneumoniae
as Causes of Chronic Asthma
Asthma, a CLD characterized by airway
obstruction, inflammation, and bronchial
hyperresponsiveness to a variety of stimuli,
including infections, is a common illness in both
pediatric and adult populations. In the United
States alone, approximately 12 million people
have asthma, resulting in health-care costs of
approximately 4.6 billion dollars annually (42).
In children, asthma is the most common reason
for hospital admissions and school absenteeism
(43). Yet the etiology and pathogenesis of this
important disease remains poorly defined.
Historically, viruses that commonly infect the
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in both provoking asthma exacerbations and in
altering responses to other environmental agents
that might be involved (44).
M. pneumoniae is a common cause of both
upper and lower respiratory infection in humans;
tracheobronchitis is the most common clinical
manifestation (45). Previously thought to cause
acute, self-limited disease primarily in persons
between 6 and 21 years of age (45), M.
pneumoniae is now known to be the cause of
pneumonia in 20% to 25% of all age groups and to
persist in certain persons for weeks to months,
resulting in prolonged reduced pulmonary
clearance and airway hyperresponsiveness
(46,47). Epidemiologic evidence links myco-
plasma infection with asthma exacerbation and
possibly with the pathogenesis of asthma (47-50).
While M. pneumoniae has been associated with
exacerbations of asthma, its role in sustaining
chronic asthma or in initiating exacerbation is
unknown. However, the proven role of mycoplas-
mas in similar chronic respiratory diseases of
numerous animal species, including M. pulmonis in
rodents, suggests that careful, systematic studies
should be undertaken in humans (45).
C. pneumoniae, the most recently described
Chlamydia species, has been associated with a
wide range of respiratory tract illnesses, from
pharyngitis to pneumonia with empyema (51). C.
pneumoniae has been isolated from 15% to 20% of
adults and children with community-acquired
pneumonia (51). On the basis of serologic results
only, C. pneumoniae has been associated with
acute exacerbations of asthma in adults (52); on
the basis of nasopharyngeal cultures, it has been
associated with asthma in children (53). In both
children and adults, the organism persists for
months in the upper respiratory tract of patients
with wheezing (54).
If M. pneumoniae, or for that matter any
infectious agent, is a causal factor in initiating and
sustaining asthma in certain persons, the agent
should be present and persistent in the lungs of
some persons with stable, chronic asthma. We have
recently undertaken a study to determine if M.
pneumoniae can be detected in the lungs of adults
with stable, chronic asthma versus asymptomatic
controls (55). To facilitate interpretation of results,
we also evaluated the presence of other fastidious
infectious agents that have previously been
implicated in the pathogenesis of asthma, including
the seven common respiratory viruses (44) and C.
pneumoniae (56,57).
M. pneumoniae was detected by PCR in 10 of
18 asthma patients and 1 of 11 controls (p = 0.02).
All patients were culture, EIA, and serologically
negative for M. pneumoniae. All PCR and
cultures were negative for C. pneumoniae and all
EIAs for respiratory viruses were negative. Nine
persons with asthma and one control exhibited
positive serology for C. pneumoniae (p = 0.05). For
C. pneumoniae, the lack of correlation between
serologic results and culture and PCR was not
unexpected. We have seen discordance between
culture and serologic results in patients with
community-acquired pneumonia (58,59), but in
these cases more patients were culture positive
than seropositive. Thus, the culture methods
we used in the study have previously been
shown to be valid.
Our failure to culture M. pneumoniae might
be explained by its extreme fastidiousness or its
low numbers. Culture is the least sensitive of the
methods used in this study for detection of M.
pneumoniae. However, the culture methods we
used in this study we also used to evaluate more
than 2,000 respiratory specimens during the
same period in patients with radiographically
confirmed, community-acquired pneumonia.
These methods have resulted in recovery of M.
pneumoniae by culture in up to 17% of patients
(G. Cassell, et al., unpub. obs.; 58,59).
Recent studies indicate that some other
mycoplasma species of human origin may be able
to survive intracellularly in chronic infections of
cell cultures (60). Likewise, some strains of M.
hyorhinis, the etiologic agent of chronic respira-
tory disease of swine, can become so adapted to
growth in the presence of cells that it is no longer
cultivable on artificial media (61). If this occurs in
vivo, organisms like M. pneumoniae could be
difficult if not impossible to recover by culture.
In the absence of other known respiratory
pathogens in other patient populations, the
presence of M. pneumoniae can be detected
longer by PCR than by either culture or serologic
test. Guinea pigs experimentally infected with M.
pneumoniae become chronically infected as
detected by PCR for up to 200 days but are culture
negative by 70 days. Also by 70 days, antibody
levels become negative (62). Thus, patients with
asthma appear chronically infected with M.
pneumoniae, despite negative culture results,
because they are PCR positive. That positive PCR
results truly reflect involvement of the lower
respiratory tract by M. pneumoniae is supported481 Vol. 4, No. 3, July–September 1998 Emerging Infectious Diseases
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by the fact that 9 of the 10 M. pneumoniae-
positive patients were positive in the
bronchoalveolar lavage (BAL), bronchial biop-
sies, or bronchial brush specimens. Furthermore,
the organism was detected in the nasopharynx or
the throat of only five of the nine asthma-positive
patients, thus indicating that detection in the
lower tract was not merely due to contamination
by organisms from the upper tract during sample
collection. More importantly, a significant
number of persons with asthma were positive in
the lower respiratory tract on repeat sampling (2
to 4 months between samples), thus indicating
persistent colonization. By cloning and sequenc-
ing the PCR product in BAL from several
representative patients, we demonstrated 100%
sequence homology with M. pneumoniae. Use of
multiple primer pairs as well as confirmation of
PCR findings in two different laboratories also
attests to the validity of the PCR results. Our
failure to detect M. pneumoniae in specimens
from age-matched control patients as well as in
specimens from 100 asymptomatic children using
the same PCR methods further verifies the
specificity of our PCR methods and argues that
finding M. pneumoniae in persons with chronic
asthma does not merely reflect a carrier state.
We have previously noted the lack of antibody
response to M. pneumoniae in both pediatric and
adult populations with community-acquired
pneumonia (G. Cassell et al, unpub. obs.;
58,59,63). Study results indicate that a subset of
infected persons do not mount an antibody
response, perhaps due to genetic differences.
Lack of antibody may in fact contribute to the
organism’s persistence. The immunomodulatory
properties of M. pneumoniae (12) also could
facilitate the organism’s persistence.
Recent studies indicate that M. pneumoniae
respiratory disease is often misdiagnosed and
inappropriately treated, which would also
contribute to persistence. Admitting physicians
chose other pathogens as the most likely agents
in 46% of the cases subsequently documented as
M. pneumoniae infections (64). Even upon correct
diagnosis, at least 10% of the patients did not
receive appropriate antibiotics during their
hospitalization.
In summary, we have demonstrated that
persons with chronic asthma, but not healthy
persons, exhibit evidence of M. pneumoniae
colonization of the lower airways. Like several
other investigators (56,57), we found more
persons with asthma than control subjects had
serologic evidence of C. pneumonia infection.
Further study is needed to determine if these
findings are an epiphenomenon or, as we expect,
a pathogenic mechanism in asthma. If the latter
is correct, greater evaluation of the process
involved is needed to further our understanding
of the pathogenesis and treatment of asthma.
Role of C. pneumoniae in Atherosclerosis
Infection was proposed as a cause of
atherosclerosis by Sir William Osler and others at
the beginning of the century (65). However, it was
not until the 1970s that experimental infection of
germ-free chickens with an avian herpesvirus
was found to produce arterial disease that
resembled human atherosclerosis (66). Associa-
tions have since been reported of human coronary
heart disease with certain gram-negative bacte-
ria (i.e., Helicobacter pylori and C. pneumoniae)
(67,68), with certain herpesviruses (especially
cytomegalovirus) (69), and with clinical markers
of chronic dental infection (70). Rather than an
exhaustive evaluation of each of these purported
associations, it seems reasonable to focus on the
respiratory pathogen, C. pneumoniae, for which
the evidence seems strongest.
C. pneumoniae, like M. pneumoniae, is a
common cause of community-acquired pneumo-
nia (70,71). C. pneumoniae infects more than 50%
of people at some point in their lives (51,71). It
can often go undiagnosed and improperly treated
because again it is fastidious and diagnostic
methods are not routinely available. Even in the
best reference laboratories, diagnosis can be a
challenge (71). It, like M. pneumoniae, is also
thought to play a role in acute asthma and chronic
bronchitis (52) as well as to cause extrapulmonary
manifestations (51,71). It, like M. pneumoniae, can
also result in persistent infection following acute
respiratory disease (54).
Eighteen seroepidemiologic studies evalu-
ated the association of C. pneumoniae infection
and cardiovascular disease (67). Most found at
least twofold or larger odds ratios; some reported
increasing odds ratios with increasing antibody
titers. The general consistency of their findings in
a total of 2,700 cases supports the existence of
some real association between C. pneumoniae
and coronary heart disease because the studies
were done in different populations, used different
criteria for cases, adjusted for potential confound-
ers to differing degrees, and were, therefore, prone482 Emerging Infectious Diseases Vol. 4, No. 3, July–September 1998
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to different biases. While diagnosis by serology has
its limitations, C. pneumoniae has been demon-
strated by a variety of laboratory techniques
(including culture, PCR, electron microscopy,
and immunocytochemistry) in the atherosclerotic
lesions of coronary arteries, carotid arteries,
aorta, smaller cerebral vessels, and larger
peripheral arteries (72-78). In the more than 13
published studies of C. pneumoniae in human
pathology samples (67), chlamydiae were present
in 257 (52%) of 495 atheromatous lesions but in
only 6 (5%) of 118 control samples of arterial
tissue, yielding a weighted odds ratio of about 10
(95% confidence interval 5-22). It seems unlikely
that sampling biases can entirely account for this
extreme difference between case and control tissue.
C. pneumoniae, an obligatory intracellular
bacterium capable of causing persistent infection
and multiplying in endothelial and smooth muscle
cells and macrophages (79), can also be dissemi-
nated by macrophages (80). Hence, some have
argued that macrophages may ingest C. pneumoniae
in the lung or elsewhere before migrating to
atheromatous lesions, in which case it may only
be a bystander. However, in two different rabbit
models, atherosclerotic changes develop only
after infection with C. pneumoniae (81,82). The
organism by itself induces the production of
cytokines (83) and adhesion molecules (84), and it
possesses an endotoxin (85) capable of modulat-
ing the host inflammatory response. Thus, the
biologic properties of C. pneumoniae make it a
logical candidate for triggering the chronic
inflammation found in atherosclerosis (82).
Finally, some studies have found rising or
elevated levels of antibodies to C. pneumoniae in
some males during the months just preceding a
heart attack (86). Recent studies indicate that
antibiotics given during or after a first heart attack
may decrease the risk of a second cardiac problem
(86-88). This finding also raises the possibility that
antibiotics may have a role in the treatment of
cardiovascular illnesses; that could be especially
beneficial in developing countries where traditional
treatments like angioplasty are expensive.
Some have proposed additional large-scale
antibiotic treatment trials in an attempt to
further prove causality. Several major issues
need to be resolved first. Ideally, one should treat
patients with documented C. pneumoniae
infection; however, reliable diagnostic methods
and treatment protocols are lacking (71). Because
most available antibiotics are bacteriostatic, not
bacteriocidal, some patients may remain infected
up to 11 months after treatment. Even if these
issues could be resolved, antibiotic treatment
trials will not prove causality, just as is the case
with U. urealyticum and CLD of prematurity or
M. pneumoniae and chronic asthma. The
nonantimicrobial effects may also influence the
outcome of such studies. For example, tetracyclines
can inhibit metalloproteinases, which may contrib-
ute to acute coronary syndromes (89). Some
macrolides have antiinflammatory effects (90-93).
Moreover, antibiotics are not selective, thus making
it impossible to determine the effects of treatment
upon C. pneumoniae versus other potential
culprits, e.g., H. pylori, which is also susceptible to
tetracyclines and macrolides. However, if antibiotic
treatment could reduce atherosclerotic events, the
public health implications could be enormous.
Causal Role of Viruses and Bacteria in
Cancer
Early in this century, Peyton Rous (2)
established beyond doubt that cancer can be
caused by an infectious agent in chickens. Since
then, evidence has accumulated that other
viruses cause cancer in a number of different
animal species (94). A growing body of research
suggests that a number of viruses, bacteria, and
parasites cause cancer in humans, thus providing
new possibilities for treatment and prevention of
cancer (94). In 1997, the World Health Organiza-
tion estimated that up to 84% of cases of some
cancers are attributable to viruses, bacteria, and
parasites and that more than 1.5 million (15%) new
cases each year could be avoided by preventing the
infectious disease associated with them (95).
H. pylori, found in the stomachs of a third of
all adults in the United States, causes inflamma-
tion of the mucous membrane of the stomach (96).
In 20% of infected persons, H. pylori induces
gastric ulcers (96). Peptic ulcer disease, a chronic
inflammatory condition of the stomach and
duodenum, affects as many as 10% of people in
the United States at some time in their lives. In
the early 20th century, pathogenesis was
believed related to stress and dietary factors.
Thus treatment focused on bed rest and bland
food. Later, gastric ulcers were believed to be
caused by the injurious effects of digestive
secretions. Following the identification of the
histamine receptor that appeared to be the
principal mediator of gastric acid secretion,
antagonists of this receptor were used for therapy483 Vol. 4, No. 3, July–September 1998 Emerging Infectious Diseases
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for peptic ulcer disease. In 1982, H. pylori was
first isolated from the human stomach, but it was
not until one decade later and after Marshall
ingested pure cultures of the organism that
causality was accepted by the medical and
scientific community (97).
In 1994, the International Agency for
Research on Cancer concluded that infection of
humans with H. pylori is causally associated with
the risk of developing adenocarcinoma of the
stomach (98), one of the most common
malignancies in the world, although relatively
uncommon in the United States (24,000 new cases
and 14,000 deaths per year). However, also in 1994,
a Consensus Panel of the National Institutes of
Health (NIH) concluded that available evidence
was insufficient to recommend eradication of H.
pylori for the purpose of preventing gastric cancer
(99). The NIH conclusion was based upon the
existence of clear examples of disparity in the
epidemiology of the two diseases. Gastric cancer is
more common in males than in females, whereas
the rates of H. pylori infection are not different for
the two genders. Some populations are
reported to have a high rate of H. pylori
infection but low rates of gastric cancer.
Gastric cancer occurs in some persons with
no evidence of H. pylori infection, and in the
United States, fewer than 1% of H. pylori–
infected persons will ever develop gastric
cancer. The strongest evidence that H. pylori
is associated with gastric cancer comes from
three prospective studies that indicate that H.
pylori–infected persons have a significantly
increased rate of gastric cancer (96,98).
Only some retrospective serologic studies
have shown an association. These disparities
indicate that factors other than H. pylori
infection are also important in gastric cancer
risk. It is possible that only some strains of H.
pylori are involved in the carcinogenic process.
For example, infection with H. pylori strains
possessing the cagA virulence factor is associated
with an increased risk of developing adenocarci-
noma of the stomach (100,101).
H. pylori is also associated with two less
common forms of cancer, non-Hodgkin lym-
phoma and mucosa-associated lymphoid tissue
lymphomas of the stomach (96). These types of
lymphomas in the stomach only arise in the
setting of H. pylori inflammation. In 70% of
H. pylori–infected patients with lymphoma,
treatment with appropriate antibiotics leads to
regression (96). This finding not only suggests a
causal role but that treatment of a bacterial
infection can actually result in regression of cancer.
Another landmark study, published in June,
1997, shows that a 12-year nationwide vaccina-
tion program against hepatitis B virus in Taiwan
resulted in a significant reduction in the number
of cases of childhood liver cancer (102). The role of
chronic infection with hepatitis B virus in the
etiology of hepatocellular carcinoma is well
established (103,104). Yet this is the first
evidence that prevention of a viral infection is
also effective against cancer. The implications
are profound. Hepatitis B infection causes some
316,000 cases of liver cancer (60% of all liver
cancer) a year worldwide (103,104). While
hepatitis C causes a further 118,000 cases (22% of
all cases) a year (103,104), some cases result from
infections with both viruses (104).
The infectious origin of carcinoma of the
cervix has long been suspected, because known
risk factors for the disease are linked to sexual
activity (105). Recent evidence indicates that
human papillomavirus (HPV) types 16 and 18 are
definitely carcinogenic in humans (94,105).
Types 31 and 33 are classified as probably
carcinogenic (94,105). In the United States,
HPVs, are associated with 82% of the 15,000
cases and 4,600 deaths due to cervical cancer
each year. They are also associated with more
than a million precancerous lesions of varying
severity. The combined direct medical costs due
to HPV are approximately 1.3 billion dollars per
year in the United States alone. Thus, effective
therapy and vaccines would have a major impact.
The pathogenic mechanisms by which
infectious agents cause cancer have not been
resolved but they appear to be diverse. In cervical
cancer, there seems to be a clear role for HPV-
encoded genes in tumor cell growth (106). In
addition to stimulation of cell proliferation,
inactivation of tumor suppressor genes, such as
p53 may be a common pathway leading to
malignancy in HPV and hepatitis B virus (106,107).
In the case of other viruses and H. pylori, active
oxygen and nitrogenic species generated by
inflammatory cells may cause DNA damage,
induce apoptosis, and modulate enzyme activities
and gene expression (94,108).
Future Research Opportunities
The basic biology of agents implicated in
chronic diseases and cancer, in contrast to many484 Emerging Infectious Diseases Vol. 4, No. 3, July–September 1998
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other infectious agents, is relatively unknown.
With rare exception, the means by which
pathogens suppress, subvert, or evade host
defenses and establish chronic or latent infection
have received little attention. Few areas of basic
research compared with microbial latency hold
greater promise of substantially contributing to
our understanding of infectious diseases and the
eventual relief of human suffering (109). Given
that the diseases discussed are among the most
common in the world, even if only some cases are
proven to be of infectious origin and effective
therapies or vaccines can be developed, the
impact on reducing health-care costs would be
substantial. Thus, further research to clarify the
etiologic agents and pathogenic mechanisms
involved in chronic diseases and cancer should be
given the highest priority.
To address the potential role of infectious
agents in chronic diseases requires a new research
paradigm compared to that which most investiga-
tors and funding agencies in infectious diseases are
accustomed. Such an approach will require high
levels of sustained funding of networks of research
groups (ideally at least for 10 years). The approach
will require collaborative research groups that
follow a large number of well-defined patients over
long periods. Success will depend on involvement
of researchers highly skilled in clinical and
epidemiologic investigation supported by labora-
tory personnel with proven expertise in detection
of a wide spectrum of fastidious organisms. No
single agent is likely to be the cause of chronic
obstructive lung disease, asthma, or cancer;
rather a number of infectious agents are likely to
have this potential, hence the need for studies of
large numbers of patients. Because the infecting
agent may only be present in the very early stages
of disease followed by an inflammatory response,
different stages of disease need to be studied. A
critical component of the investigative approach
will be the ability to determine the genetic
background and immune response of the patients.
The randomized, controlled clinical trial
provides a scientific experiment that conforms to
the standard model of biomedical research and is
undoubtedly the best theoretical approach to
evaluating any new therapy (110,111). Antibiotic
treatment trials are commonly used to prove an
infectious etiology. While clinical trials are at
their best in evaluating the efficacy of therapies
for acute diseases, clinical trials may not be the
best approach for evaluating the efficacy of
therapies for chronic diseases, most of which are
likely to be complex, multifactorial illnesses in
which behavioral and lifestyle factors play an
important role. Some of the difficulties associated
with this approach have already been discussed.
Well-defined, relevant animal models will be
extremely important in elucidating the role of
infectious agents in chronic inflammatory diseases.
The animal studied should be the most genetically
susceptible to the infecting agent and chronic
infection. All too often inappropriate conclusions
are based on use of a single strain of a single species.
The value of using a naturally occurring disease
with features that closely parallel those of the
human disease cannot be overestimated.
As we attempt to prove the role of infection in
chronic inflammatory diseases and cancer, the
biggest challenge will be convincing peer review
groups who establish research priorities and who
facilitate funding decisions that these are not
“fishing expeditions.” Likewise, the challenge will
be to convince journal editors that the findings are
not merely coincidental. To make rapid progress we
must keep an open mind and accept the likely
possibility that fulfillment of Koch’s postulates for
infectious agents involved in chronic inflammatory
diseases and cancer may not be possible.
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Institute of Allergy and Infectious Diseases of NIH.
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cilors of the National Center for Infectious Diseases,
CDC, and is the immediate past chair of the board.
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